Market capitalization | $14.62m |
Enterprise Value | $9.23m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.22 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-27.32m |
Free Cash Flow (TTM) Free Cash Flow | $-21.98m |
Cash position | $5.01m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
2 Analysts have issued a BriaCell Therapeutics Corp forecast:
2 Analysts have issued a BriaCell Therapeutics Corp forecast:
Jan '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.13 -0.13 |
550%
550%
|
|
EBITDA | -27 -27 |
14%
14%
|
EBIT (Operating Income) EBIT | -27 -27 |
14%
14%
|
Net Profit | -12 -12 |
8%
8%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
Head office | Canada |
CEO | William Williams |
Employees | 18 |
Founded | 2006 |
Website | www.briacell.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.